Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: EIF3K

Gene summary for EIF3K

Gene summary.

Gene information	Species	Human
	Gene symbol	EIF3K
	Gene ID	27335
	Gene name	eukaryotic translation initiation factor 3 subunit K
	Gene Alias	ARG134
	Cytomap	19q13.2
	Gene Type	protein-coding
	GO ID	GO:0001732
	UniProtAcc	K7ERF1

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
27335	EIF3K	P16T-E	Human	Esophagus	ESCC	3.95e-39	1.00e+00	0.1153
27335	EIF3K	P17T-E	Human	Esophagus	ESCC	1.09e-30	2.02e+00	0.1278
27335	EIF3K	P19T-E	Human	Esophagus	ESCC	1.76e-18	2.83e+00	0.1662
27335	EIF3K	P20T-E	Human	Esophagus	ESCC	1.88e-69	2.26e+00	0.1124
27335	EIF3K	P21T-E	Human	Esophagus	ESCC	5.22e-63	1.62e+00	0.1617
27335	EIF3K	P22T-E	Human	Esophagus	ESCC	2.27e-98	2.34e+00	0.1236
27335	EIF3K	P23T-E	Human	Esophagus	ESCC	1.08e-67	2.96e+00	0.108
27335	EIF3K	P24T-E	Human	Esophagus	ESCC	2.43e-69	1.92e+00	0.1287
27335	EIF3K	P26T-E	Human	Esophagus	ESCC	8.65e-99	2.36e+00	0.1276
27335	EIF3K	P27T-E	Human	Esophagus	ESCC	1.38e-79	2.02e+00	0.1055
27335	EIF3K	P28T-E	Human	Esophagus	ESCC	2.24e-74	2.55e+00	0.1149
27335	EIF3K	P30T-E	Human	Esophagus	ESCC	2.82e-56	2.98e+00	0.137
27335	EIF3K	P31T-E	Human	Esophagus	ESCC	4.69e-83	2.02e+00	0.1251
27335	EIF3K	P32T-E	Human	Esophagus	ESCC	8.25e-96	2.98e+00	0.1666
27335	EIF3K	P36T-E	Human	Esophagus	ESCC	2.63e-21	1.14e+00	0.1187
27335	EIF3K	P37T-E	Human	Esophagus	ESCC	1.99e-58	1.72e+00	0.1371
27335	EIF3K	P38T-E	Human	Esophagus	ESCC	4.07e-30	2.27e+00	0.127
27335	EIF3K	P39T-E	Human	Esophagus	ESCC	2.52e-22	7.67e-01	0.0894
27335	EIF3K	P40T-E	Human	Esophagus	ESCC	5.27e-38	1.49e+00	0.109
27335	EIF3K	P42T-E	Human	Esophagus	ESCC	7.31e-46	1.72e+00	0.1175

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
GC		CAG: Chronic atrophic gastritis
		CAG with IM: Chronic atrophic gastritis with intestinal metaplasia
		CSG: Chronic superficial gastritis
		GC: Gastric cancer
		SIM: Severe intestinal metaplasia
		WIM: Wild intestinal metaplasia
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00021819	Breast	Precancer	cytoplasmic translation	80/1080	148/18723	1.59e-59	8.54e-56	80
GO:00226139	Breast	Precancer	ribonucleoprotein complex biogenesis	79/1080	463/18723	2.11e-18	1.03e-15	79
GO:00718269	Breast	Precancer	ribonucleoprotein complex subunit organization	48/1080	227/18723	2.68e-15	8.45e-13	48
GO:00226189	Breast	Precancer	ribonucleoprotein complex assembly	47/1080	220/18723	3.47e-15	1.03e-12	47
GO:00064138	Breast	Precancer	translational initiation	30/1080	118/18723	3.23e-12	5.58e-10	30
GO:00064179	Breast	Precancer	regulation of translation	67/1080	468/18723	4.71e-12	7.64e-10	67
GO:00064466	Breast	Precancer	regulation of translational initiation	19/1080	79/18723	7.99e-08	4.60e-06	19
GO:00021838	Breast	Precancer	cytoplasmic translational initiation	11/1080	34/18723	1.87e-06	6.63e-05	11
GO:00017328	Breast	Precancer	formation of cytoplasmic translation initiation complex	7/1080	16/18723	1.50e-05	3.71e-04	7
GO:000218114	Breast	IDC	cytoplasmic translation	82/1434	148/18723	2.60e-52	1.48e-48	82
GO:002261314	Breast	IDC	ribonucleoprotein complex biogenesis	83/1434	463/18723	2.01e-13	5.20e-11	83
GO:007182614	Breast	IDC	ribonucleoprotein complex subunit organization	52/1434	227/18723	5.18e-13	1.21e-10	52
GO:002261814	Breast	IDC	ribonucleoprotein complex assembly	51/1434	220/18723	5.32e-13	1.21e-10	51
GO:000641313	Breast	IDC	translational initiation	31/1434	118/18723	7.29e-10	7.52e-08	31
GO:000641714	Breast	IDC	regulation of translation	74/1434	468/18723	1.67e-09	1.53e-07	74
GO:000644613	Breast	IDC	regulation of translational initiation	20/1434	79/18723	1.40e-06	6.00e-05	20
GO:000218313	Breast	IDC	cytoplasmic translational initiation	12/1434	34/18723	4.35e-06	1.53e-04	12
GO:000173213	Breast	IDC	formation of cytoplasmic translation initiation complex	8/1434	16/18723	8.56e-06	2.47e-04	8
GO:000218124	Breast	DCIS	cytoplasmic translation	82/1390	148/18723	2.21e-53	1.25e-49	82
GO:002261324	Breast	DCIS	ribonucleoprotein complex biogenesis	83/1390	463/18723	3.65e-14	1.09e-11	83

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

EIF3K

SNV

Missense_Mutation

c.403N>C

p.Glu135Gln

p.E135Q

Q9UBQ5

protein_coding

tolerated(0.05)

benign(0.22)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

EIF3K

SNV

Missense_Mutation

rs750097473

c.232N>G

p.Pro78Ala

p.P78A

Q9UBQ5

protein_coding

deleterious(0.01)

probably_damaging(0.975)

TCGA-AC-A3W6-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Unknown

EIF3K

SNV

Missense_Mutation

c.70N>C

p.Glu24Gln

p.E24Q

Q9UBQ5

protein_coding

tolerated(0.06)

benign(0.3)

TCGA-BH-A0HK-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

EIF3K

SNV

Missense_Mutation

novel

c.577N>A

p.Glu193Lys

p.E193K

Q9UBQ5

protein_coding

deleterious(0)

probably_damaging(0.957)

TCGA-D8-A73U-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

tamoxiphen

EIF3K

SNV

Missense_Mutation

c.487N>A

p.Gly163Arg

p.G163R

Q9UBQ5

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-AZ-4313-01

Colorectum

colon adenocarcinoma

Female

<65

I/II

Unknown

EIF3K

SNV

Missense_Mutation

novel

c.175G>C

p.Ala59Pro

p.A59P

Q9UBQ5

protein_coding

tolerated(0.26)

benign(0)

TCGA-AP-A1DR-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

cisplatin

EIF3K

SNV

Missense_Mutation

novel

c.188C>T

p.Thr63Ile

p.T63I

Q9UBQ5

protein_coding

tolerated(0.46)

benign(0.003)

TCGA-AX-A06F-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

carboplatin

EIF3K

SNV

Missense_Mutation

novel

c.208N>A

p.Leu70Met

p.L70M

Q9UBQ5

protein_coding

deleterious(0.03)

probably_damaging(0.966)

TCGA-B5-A1MX-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Hormone Therapy

megace

EIF3K

SNV

Missense_Mutation

rs764778412

c.299G>A

p.Arg100Gln

p.R100Q

Q9UBQ5

protein_coding

tolerated(0.63)

benign(0.018)

TCGA-BS-A0UF-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

EIF3K

SNV

Missense_Mutation

c.416N>A

p.Arg139Gln

p.R139Q

Q9UBQ5

protein_coding

tolerated(0.1)

possibly_damaging(0.796)

TCGA-D1-A17Q-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

Page: 1 2 3

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1